Holen Sie sich die Stockscreener-App
24.07
0.82%
-0.20
Handel nachbörslich:
23.63
-0.44
-1.83%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Novato's Ultragenyx tries — again — to convince FDA to approve brain disease gene therapy - The Business Journals
Ultragenyx resubmits BLA for Sanfilippo syndrome gene therapy By Investing.com - Investing.com Canada
Ultragenyx resubmits gene therapy for rare neuro disease to FDA - Endpoints News
Ultragenyx (RARE) Seeks FDA Approval for Gene Therapy UX111 - GuruFocus
Ultragenyx Resubmits UX111 Gene Therapy for FDA Review - TipRanks
Ultragenyx resubmits BLA for Sanfilippo syndrome gene therapy - Investing.com
Ultragenyx Resubmits FDA Application for Potential Therapy for Rare Neurodegeneration Disease - marketscreener.com
Ultragenyx Pharmaceutical Resubmits BLA For UX111 AAV9 Gene Therapy - Nasdaq
Ultragenyx Resubmits BLA for UX111 Gene Therapy - TradingView
FDA to review resubmitted gene therapy for fatal Sanfilippo syndrome - Stock Titan
RARE Stock Slips 3% Today — What’s Up With Ultragenyx’s Gene Therapy For Sanfilippo Syndrome? - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
Barclays reiterates Overweight rating on Ultragenyx Pharma stock - Investing.com
Barclays reiterates Overweight rating on Ultragenyx Pharma stock By Investing.com - Investing.com UK
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring a 163% Potential Upside Amidst Promising Rare Disease Treatments - DirectorsTalk Interviews
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today - AOL.com
Precision Trading with Ultragenyx Pharmaceutical Inc. (RARE) Risk Zones - Stock Traders Daily
Ultragenyx Pharmaceutical's Phase III Study Fails to Meet Primary Endpoint, Analysts Cut Price Targets - Intellectia AI
Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies - Sahm
Ultragenyx Pharmaceutical (RARE) Valuation Check As 2025 Revenue Guidance Signals Stronger Growth - Sahm
Ultragenyx Pharmaceutical Inc. Faces Setback as Phase III Studies Fail to Meet Primary Endpoint - Intellectia AI
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Emerald Mutual Fund Advisers Trust Sells 52,515 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline - Seeking Alpha
Ultragenyx (RARE) Lifts 2025 Revenue Guidance, But What Does It Reveal About Growth Visibility? - Sahm
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring the 184% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Campbell & CO Investment Adviser LLC Grows Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Lobbying Update: $60,000 of ULTRAGENYX PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
2026-01-16 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Shareholders to Reach Out | NDAQ:RARE | Press Release - Stockhouse
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
Cantor Fitzgerald maintains $118 target on Ultragenyx stock - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Dividend Watch: What are the future prospects of Ultragenyx Pharmaceutical Inc2025 Earnings Impact & Growth Focused Investment Plans - baoquankhu1.vn
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Upgraded 2025 Guidance And DTX401 BLA Completion - Sahm
Will Ultragenyx Pharmaceutical Inc outperform tech stocksStop Loss & Consistent Income Trade Recommendations - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Dexcom (DXCM) and Health Catalyst (HCAT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Quarterly Recap: Is Ultragenyx Pharmaceutical Inc stock ready for breakoutTrend Reversal & Daily Chart Pattern Signals - Bộ Nội Vụ
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 39.1% One Year Decline? - Yahoo Finance
Ultragenyx reports preliminary 2025 revenue of $672-674 million By Investing.com - Investing.com Nigeria
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Revenue Beat And Gene Therapy Catalysts Update - Yahoo Finance
Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery - Insider Monkey
Ultragenyx reports preliminary 2025 revenue of $672-674 million - Investing.com
Ultragenyx Pharmaceutical Inc. Reports Preliminary 2025 Revenue of $672 Million to $674 Million, Exceeding Guidance - Quiver Quantitative
Ultragenyx provides financial and business updates at J.P. Morgan Annual Healthcare Conference - marketscreener.com
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference - The Manila Times
SG Americas Securities LLC Purchases Shares of 125,429 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Analysts lower Ultragenyx (RARE) target but stay bullish - MSN
2026-01-11 | Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation | NDAQ:RARE | Press Release - Stockhouse
1.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):